Oppenheimer & Co. Inc. increased its holdings in Mylan N.V. (NASDAQ:MYL) by 15.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,781 shares of the company’s stock after purchasing an additional 10,954 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Mylan were worth $2,629,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. lifted its holdings in shares of Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares during the last quarter. BT Investment Management Ltd purchased a new position in shares of Mylan during the third quarter valued at approximately $142,000. Global X Management Co. LLC lifted its holdings in shares of Mylan by 59.2% during the second quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after purchasing an additional 1,786 shares during the last quarter. Doliver Capital Advisors LP purchased a new position in shares of Mylan during the second quarter valued at approximately $201,000. Finally, Eagle Global Advisors LLC purchased a new position in shares of Mylan during the second quarter valued at approximately $205,000. 73.86% of the stock is currently owned by institutional investors.
Mylan N.V. (MYL) opened at $37.41 on Wednesday. The firm has a market cap of $20,084.17, a price-to-earnings ratio of 7.97, a P/E/G ratio of 2.05 and a beta of 1.38. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87.
Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.38 EPS. analysts expect that Mylan N.V. will post 4.56 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the stock. Citigroup upgraded shares of Mylan from a “neutral” rating to a “buy” rating and lifted their target price for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. Royal Bank Of Canada restated a “sector perform” rating and issued a $32.00 price objective (down from $33.00) on shares of Mylan in a report on Thursday, August 10th. Cowen restated a “hold” rating and issued a $30.00 price objective (down from $43.00) on shares of Mylan in a report on Wednesday, August 9th. Wells Fargo & Company set a $32.00 target price on shares of Mylan and gave the stock a “hold” rating in a research report on Wednesday, October 4th. Finally, Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the stock a “hold” rating in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Mylan presently has a consensus rating of “Buy” and a consensus target price of $41.49.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.